Skip to main content

Table 3 Most common adverse events by CTCAE grade (≥20%)

From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

Preferred term mITT population (N =82)
Grade 1/2 Grade 3 Grade 4 Grade 5 All grades
Hematologic TEAEs, n (%)
 Thrombocytopenia 30 (36.6) 23 (28.0) 19 (23.2) 0 72 (87.8)
 Anemia 24 (29.3) 43 (52.4) 4 (4.9) 0 71 (86.6)
 Leukopenia 36 (43.9) 27 (32.9) 5 (6.1) 0 68 (82.9)
 Lymphopenia 28 (34.1) 24 (29.3) 11 (13.4) 0 63 (76.8)
 Neutropenia 26 (31.7) 20 (24.4) 13 (15.9) 0 59 (72.0)
Non-hematologic TEAEs, n (%)
 Nausea 58 (70.7) 6 (7.3) 0 0 64 (78.0)
 Hyponatremia 31 (37.8) 24 (29.3) 0 0 55 (67.1)
 Weight decreased 54 (65.9) 0 0 0 54 (65.9)
 Decreased appetite 48 (58.5) 3 (3.7) 0 0 51 (62.2)
 Asthenia 41 (50.0) 8 (9.8) 0 0 49 (59.8)
 Hyperglycemia 38 (46.3) 7 (8.5) 1 (1.2) 0 46 (56.1)
 Vomiting 35 (42.7) 6 (7.3) 0 0 41 (50.0)
 Hypocalcemia 30 (36.6) 5 (6.1) 1 (1.2) 0 36 (43.9)
 Hypokalemia 21 (25.6) 9 (11.0) 1 (1.2) 0 31 (37.8)
 Hypoalbuminemia 25 (30.5) 1 (1.2) 0 0 26 (31.7)
 Diarrhea 22 (26.8) 3 (3.7) 0 0 25 (30.5)
 Lung infection 3 (3.7) 20 (24.4) 1 (1.2) 1 (1.2) 25 (30.5)
 Hypophosphatemia 14 (17.1) 5 (6.1) 0 0 19 (23.2)
 Aspartate aminotransferase increased 17 (20.7) 0 2 (2.4) 0 19 (23.2)
 Alanine aminotransferase increased 15 (18.3) 2 (2.4) 1 (1.2) 0 18 (22.0)
 Insomnia 18 (22.0) 0 0 0 18 (22.0)
  1. When multiple adverse events occurred in the same patient, the highest CTCAE grade was used for statistics; when the same patient had multiple adverse events under the same SOC or PT, the highest CTCAE grade was used for statistics